$226.97 Million in Sales Expected for Merit Medical Systems, Inc. (MMSI) This Quarter

Equities research analysts expect that Merit Medical Systems, Inc. (NASDAQ:MMSI) will post sales of $226.97 million for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Merit Medical Systems’ earnings. The highest sales estimate is $229.08 million and the lowest is $225.23 million. Merit Medical Systems posted sales of $190.90 million in the same quarter last year, which would indicate a positive year over year growth rate of 18.9%. The firm is scheduled to announce its next earnings report on Wednesday, February 27th.

According to Zacks, analysts expect that Merit Medical Systems will report full-year sales of $875.49 million for the current financial year, with estimates ranging from $870.46 million to $878.58 million. For the next financial year, analysts forecast that the firm will report sales of $977.50 million, with estimates ranging from $934.00 million to $1.04 billion. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Merit Medical Systems.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings data on Thursday, October 25th. The medical instruments supplier reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.05. Merit Medical Systems had a return on equity of 10.86% and a net margin of 4.72%. The firm had revenue of $221.66 million for the quarter, compared to analysts’ expectations of $217.62 million.

A number of research analysts recently commented on MMSI shares. Zacks Investment Research cut Merit Medical Systems from a “buy” rating to a “hold” rating in a report on Friday, July 20th. Needham & Company LLC boosted their target price on Merit Medical Systems from $54.00 to $67.00 and gave the company a “buy” rating in a research report on Tuesday, July 24th. Canaccord Genuity boosted their target price on Merit Medical Systems from $60.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, July 24th. Raymond James boosted their target price on Merit Medical Systems from $59.00 to $61.00 and gave the company an “outperform” rating in a research report on Tuesday, July 24th. Finally, Barrington Research boosted their target price on Merit Medical Systems from $50.00 to $61.00 and gave the company an “outperform” rating in a research report on Tuesday, July 24th. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $68.10.

In other Merit Medical Systems news, Director F. Ann Millner sold 9,593 shares of the business’s stock in a transaction that occurred on Wednesday, October 31st. The stock was sold at an average price of $56.92, for a total value of $546,033.56. Following the sale, the director now owns 7,891 shares of the company’s stock, valued at $449,155.72. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Ronald Frost sold 5,257 shares of the business’s stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $61.31, for a total value of $322,306.67. Following the completion of the sale, the chief operating officer now directly owns 5,257 shares in the company, valued at approximately $322,306.67. The disclosure for this sale can be found here. 5.00% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of the company. Piedmont Investment Advisors Inc. increased its position in shares of Merit Medical Systems by 7.4% during the third quarter. Piedmont Investment Advisors Inc. now owns 12,588 shares of the medical instruments supplier’s stock worth $774,000 after acquiring an additional 863 shares during the period. Metropolitan Life Insurance Co. NY increased its position in shares of Merit Medical Systems by 6.4% during the second quarter. Metropolitan Life Insurance Co. NY now owns 15,891 shares of the medical instruments supplier’s stock worth $814,000 after acquiring an additional 956 shares during the period. Piedmont Investment Advisors LLC increased its position in shares of Merit Medical Systems by 9.1% during the second quarter. Piedmont Investment Advisors LLC now owns 11,725 shares of the medical instruments supplier’s stock worth $600,000 after acquiring an additional 981 shares during the period. Amalgamated Bank increased its position in shares of Merit Medical Systems by 14.4% during the second quarter. Amalgamated Bank now owns 8,025 shares of the medical instruments supplier’s stock worth $411,000 after acquiring an additional 1,010 shares during the period. Finally, United Services Automobile Association increased its position in shares of Merit Medical Systems by 11.1% during the second quarter. United Services Automobile Association now owns 11,087 shares of the medical instruments supplier’s stock worth $568,000 after acquiring an additional 1,108 shares during the period. 87.09% of the stock is currently owned by institutional investors and hedge funds.

MMSI opened at $59.16 on Wednesday. Merit Medical Systems has a one year low of $36.21 and a one year high of $66.34. The company has a market capitalization of $3.34 billion, a P/E ratio of 46.22, a price-to-earnings-growth ratio of 2.82 and a beta of 1.19. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.47 and a current ratio of 2.77.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets various disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through Cardiovascular and Endoscopy segments. It provides various peripheral intervention products, including access, angiography, intervention, and drainage and biopsy products to alleviate patients suffering from peripheral vascular and non-vascular diseases; and cardiac intervention products to aid in the treatment of various cardiac conditions specific to interventional cardiology and electrophysiology, including cardiac rhythm management and lead management.

Featured Story: Risk Tolerance

Get a free copy of the Zacks research report on Merit Medical Systems (MMSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merit Medical Systems (NASDAQ:MMSI)

Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply